What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Diabetes mellitus
- Type 2 diabetes
Diabetes mellitus, Internal medicine, Type 2 diabetes, Endocrinology and Surgery are his primary areas of study.
David R. Matthews works in the field of Diabetes mellitus, namely Type 2 Diabetes Mellitus.
His research in Type 2 Diabetes Mellitus tackles topics such as Adverse effect which are related to areas like Guideline.
His work in Internal medicine addresses subjects such as Placebo, which are connected to disciplines such as Gastroenterology.
His Type 2 diabetes research integrates issues from Metformin, Disease management, Family medicine and Intensive care medicine.
His Disease management study combines topics from a wide range of disciplines, such as Vildagliptin, Lixisenatide and Insulin degludec.
His most cited work include:
- Homeostasis model assessment : insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man (24158 citations)
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) (14520 citations)
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study (6484 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Diabetes mellitus, Endocrinology, Type 2 diabetes and Insulin.
His study in Internal medicine is interdisciplinary in nature, drawing from both Placebo and Canagliflozin.
He is interested in Type 2 Diabetes Mellitus, which is a field of Diabetes mellitus.
His studies in Type 2 diabetes integrate themes in fields like Gastroenterology, Adverse effect, Disease management and Family medicine.
David R. Matthews combines subjects such as Type 1 diabetes and Homeostasis with his study of Insulin.
David R. Matthews combines subjects such as Clinical trial, Glycemic and Smoking cessation with his study of Intensive care medicine.
He most often published in these fields:
- Internal medicine (72.29%)
- Diabetes mellitus (60.29%)
- Endocrinology (49.43%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (72.29%)
- Type 2 diabetes (50.86%)
- Canagliflozin (9.14%)
In recent papers he was focusing on the following fields of study:
David R. Matthews mostly deals with Internal medicine, Type 2 diabetes, Canagliflozin, Diabetes mellitus and Placebo.
His research integrates issues of Liraglutide, Semaglutide and Empagliflozin in his study of Internal medicine.
His Type 2 diabetes research incorporates elements of Metformin, Insulin, Kidney disease, Gastroenterology and Combination therapy.
His study in Diabetes mellitus is interdisciplinary in nature, drawing from both Heart failure, Intensive care medicine, Disease, Myocardial infarction and Placebo-controlled study.
His studies in Placebo integrate themes in fields like Diabetic retinopathy, Clinical trial, Adverse effect, Nephropathy and Post-hoc analysis.
The Type 2 Diabetes Mellitus study which covers Clinical endpoint that intersects with Randomization.
Between 2016 and 2021, his most popular works were:
- Canagliflozin and cardiovascular and renal events in type 2 diabetes (2888 citations)
- Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study) (228 citations)
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials (224 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Diabetes mellitus
- Type 2 diabetes
His primary areas of investigation include Internal medicine, Type 2 diabetes, Canagliflozin, Diabetes mellitus and Placebo.
His Internal medicine research is mostly focused on the topic Randomized controlled trial.
His studies deal with areas such as Diabetic retinopathy, Insulin and Hazard ratio as well as Type 2 diabetes.
His Canagliflozin study integrates concerns from other disciplines, such as Empagliflozin, Albuminuria, Renal function and Heart failure.
His Diabetes mellitus research includes themes of Placebo-controlled study and Intensive care medicine.
His Placebo study deals with Clinical trial intersecting with Adverse effect and Glycated haemoglobin.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
